B-intervention	0	8	Exercise
I-intervention	9	13	type
O	14	17	and
B-condition	18	21	fat
I-condition	22	26	mass
I-condition	27	31	loss
O	32	40	regulate
O	41	47	breast
O	48	54	cancer
O	54	55	-
O	55	62	related
O	63	66	sex
O	67	75	hormones
O	76	78	in
O	79	84	obese
O	85	88	and
O	89	99	overweight
O	100	114	postmenopausal
O	115	120	women
O	120	121	.

O	122	125	The
O	126	129	aim
O	130	132	of
O	133	136	the
O	137	142	study
O	143	146	was
O	147	149	to
O	150	157	examine
O	158	161	the
O	162	169	effects
O	170	172	of
O	173	174	a
O	175	179	time
O	179	180	-
O	180	187	matched
O	188	197	endurance
O	198	204	versus
O	205	215	concurrent
O	216	224	training
O	225	227	on
O	228	239	circulating
O	240	243	sex
O	244	251	hormone
O	252	258	levels
O	259	262	and
O	263	267	body
O	268	279	composition
O	280	282	in
O	283	297	postmenopausal
O	298	303	women
O	303	304	.

B-total-participants	305	311	Thirty
I-total-participants	311	312	-
I-total-participants	312	316	five
B-eligibility	317	326	sedentary
I-eligibility	327	330	and
I-eligibility	331	336	obese
I-eligibility	337	351	postmenopausal
I-eligibility	352	357	women
O	358	362	were
O	363	372	recruited
O	373	376	and
O	377	385	randomly
O	386	393	divided
O	394	398	into
O	399	408	endurance
O	409	417	training
O	418	419	(
O	419	421	EN
O	421	422	,
O	423	424	n
O	425	426	=
B-intervention-participants	427	429	10
O	429	430	)
O	430	431	,
O	432	442	concurrent
O	443	451	training
O	452	453	(
O	453	456	CON
O	456	457	,
O	458	459	n
O	460	461	=
B-intervention-participants	462	464	13
O	464	465	)
O	465	466	,
O	467	469	or
B-control	470	477	control
I-control	478	483	group
O	484	485	(
O	485	486	C
O	486	487	,
O	488	489	n
O	490	491	=
B-control-participants	492	494	12
O	494	495	)
O	495	496	.

O	497	509	Participants
O	510	514	took
O	515	519	part
O	520	522	in
O	523	524	a
O	525	527	12
O	527	528	-
O	528	532	week
O	533	543	supervised
O	544	556	intervention
O	556	557	,
O	558	566	training
O	567	568	3
O	569	573	days
O	573	574	/
O	574	578	week
O	579	582	and
O	583	585	60
O	586	589	min
O	589	590	/
O	590	597	session
O	597	598	.

O	599	605	Before
O	606	609	and
O	610	615	after
O	616	619	the
O	620	632	intervention
O	632	633	,
O	634	638	body
O	639	650	composition
O	651	654	was
O	655	663	assessed
O	663	664	,
O	665	668	and
O	669	674	blood
O	675	682	samples
O	683	687	were
O	688	696	obtained
O	697	699	to
O	700	708	evaluate
O	709	718	estradiol
O	718	719	,
O	720	732	testosterone
O	732	733	,
O	734	738	DHEA
O	738	739	-
O	739	740	S
O	740	741	,
O	742	745	and
O	746	750	SHBG
O	750	751	.

O	752	754	In
O	755	763	response
O	764	766	to
O	767	775	training
O	775	776	,
O	777	778	a
B-outcome	779	788	reduction
I-outcome	789	791	in
I-outcome	792	797	total
I-outcome	798	801	fat
I-outcome	802	806	mass
O	807	810	was
O	811	816	found
O	817	818	(
O	818	819	5
O	819	820	.
O	820	821	3
O	821	822	%
O	822	823	;
O	824	825	P
O	826	827	<
O	828	829	0
O	829	830	.
O	830	832	05
O	832	833	)
O	833	834	,
O	835	840	while
O	841	843	an
B-outcome	844	852	increase
I-outcome	853	855	in
I-outcome	856	860	lean
I-outcome	861	865	body
I-outcome	866	870	mass
O	871	874	was
O	875	883	observed
O	884	886	in
O	887	890	the
O	891	894	CON
O	895	900	group
O	901	902	(
O	902	903	1
O	903	904	.
O	904	905	5
O	905	906	%
O	906	907	;
O	908	909	P
O	910	911	<
O	912	913	0
O	913	914	.
O	914	916	05
O	916	917	)
O	917	918	.

O	919	924	There
O	925	928	was
O	929	930	a
O	931	942	significant
B-outcome	943	951	decrease
I-outcome	952	954	in
I-outcome	955	959	DHEA
I-outcome	959	960	-
I-outcome	960	961	S
O	962	963	(
O	963	964	-
O	965	967	13
O	967	968	%
O	968	969	)
O	969	970	,
O	971	976	total
O	977	978	(
O	978	979	-
O	980	982	40
O	982	983	%
O	983	984	)
O	985	988	and
B-outcome	989	993	free
I-outcome	994	1006	testosterone
O	1007	1008	(
O	1008	1009	-
O	1010	1012	41
O	1012	1013	%
O	1013	1014	)
O	1015	1017	in
O	1018	1021	the
O	1022	1024	EN
O	1025	1030	group
O	1030	1031	,
O	1032	1037	while
O	1038	1040	in
O	1041	1044	the
O	1045	1048	CON
O	1049	1054	group
O	1054	1055	,
O	1056	1061	total
O	1062	1063	(
O	1063	1065	25
O	1065	1066	%
O	1066	1067	)
O	1068	1071	and
O	1072	1076	free
O	1077	1089	testosterone
O	1090	1091	(
O	1091	1093	21
O	1093	1094	%
O	1094	1095	)
O	1096	1105	increased
O	1106	1119	significantly
O	1120	1121	(
O	1121	1122	P
O	1123	1124	<
O	1125	1126	0
O	1126	1127	.
O	1127	1129	05
O	1129	1130	)
O	1130	1131	.

O	1132	1136	When
O	1137	1149	participants
O	1150	1154	were
O	1155	1165	stratified
O	1166	1175	according
O	1176	1178	to
O	1179	1182	fat
O	1183	1187	mass
O	1188	1192	loss
O	1193	1194	(
O	1194	1195	>
O	1196	1198	or
O	1199	1200	<
O	1201	1202	2
O	1203	1205	kg
O	1205	1206	)
O	1206	1207	,
O	1208	1209	a
O	1210	1223	statistically
O	1224	1235	significant
O	1236	1244	increase
O	1245	1247	in
B-outcome	1248	1259	circulating
I-outcome	1260	1264	SHBG
O	1265	1266	(
O	1266	1268	21
O	1268	1269	%
O	1269	1270	)
O	1271	1274	and
O	1275	1283	decrease
O	1284	1286	in
B-outcome	1287	1291	DHEA
I-outcome	1291	1292	-
I-outcome	1292	1293	S
O	1294	1295	(
O	1295	1296	-
O	1297	1299	13
O	1299	1300	%
O	1300	1301	)
O	1302	1306	were
O	1307	1312	found
O	1312	1313	.

O	1314	1317	The
O	1318	1322	type
O	1323	1325	of
O	1326	1334	exercise
O	1335	1338	and
O	1339	1347	exercise
O	1347	1348	-
O	1348	1355	induced
O	1356	1359	fat
O	1360	1364	mass
O	1365	1369	loss
O	1370	1374	seem
O	1375	1377	to
O	1378	1384	modify
O	1385	1388	the
O	1389	1392	sex
O	1393	1400	hormone
O	1401	1408	profile
O	1409	1411	in
O	1412	1426	postmenopausal
O	1427	1432	women
O	1433	1437	that
O	1438	1440	is
O	1441	1443	an
O	1444	1455	established
O	1456	1460	risk
O	1461	1467	factor
O	1468	1470	of
O	1471	1477	breast
O	1478	1484	cancer
O	1484	1485	.

O	1486	1490	Thus
O	1490	1491	,
O	1492	1496	this
O	1497	1502	study
O	1503	1511	provides
O	1512	1522	additional
O	1523	1532	evidences
O	1533	1535	to
O	1536	1539	the
O	1540	1550	intricated
O	1551	1562	interaction
O	1563	1568	among
O	1569	1572	sex
O	1573	1581	hormones
O	1581	1582	,
O	1583	1590	adipose
O	1591	1597	tissue
O	1597	1598	,
O	1599	1602	and
O	1603	1609	muscle
O	1610	1614	mass
O	1615	1617	in
O	1618	1632	postmenopausal
O	1633	1638	women
O	1638	1639	.
